Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | VHL | P40337 | 1/20 | 0.41 |
| ▸ | ELOC | Q15369 | 1/20 | 0.41 |
| ▸ | ELOB | Q15370 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30829218 | 1.00 | S100A4 (0.43) | S100A4VHLELOCELOBPTPRC | |
| SCHEMBL2594793 | 0.84 | S100A4 (0.43) | S100A4PTPRCPBRM1BCL2MCL1 | |
| SCHEMBL29922129 | 0.84 | S100A4 (0.43) | S100A4PTPRCPBRM1BCL2MCL1 | |
| SCHEMBL69249 | 0.81 | VHL (0.64) | S100A4VHLELOCELOBPTPRC | |
| SCHEMBL5858953 | 0.80 | ALDH1A1 (0.50) | VHLELOCELOBPTPRCPBRM1 | |
| SCHEMBL5203764 | 0.78 | VHL (0.51) | S100A4VHLELOCELOBPTPRC | |
| Ethylene SCHEMBL8101571 | 0.78 | VHL (0.60) | S100A4VHLELOCELOBPTPRC | |
| SCHEMBL4152484 | 0.76 | NOTUM (0.49) | VHLELOCELOBCA1CA2 | |
| SCHEMBL10054228 | 0.76 | EPHX2 (0.49) | VHLELOCELOBCA1CA2 | |
| SCHEMBL68898 | 0.76 | VHL (0.68) | S100A4VHLELOCELOBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-117794924-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115703768-A | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166726-B2 | Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| EP-0948478-B1 | ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6087505-A | Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives | ALLERGAN SALES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| US-5728846-A | RETENOIDS, RETINOID ACTIVITY; AGONISTS, ANTAGONISTS | ALLERGAN (US) | 1998-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265449-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, RARG, NR2E3 | S100A4 4188/4885VHL 2005/4885ELOC 3301/4885 |
| US-20030130515-A1 | Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity | RXRG, NR2E3, RARG | S100A4 4159/4885VHL 2237/4885ELOC 3357/4885 |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | S100A4 4638/4885VHL 932/4885ELOC 1937/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | S100A4 1971/4885VHL 545/4885ELOC 303/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | S100A4 3331/4885VHL 2166/4885ELOC 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.